keyword
MENU ▼
Read by QxMD icon Read
search

brain tumors pet

keyword
https://www.readbyqxmd.com/read/28737579/prostate-specific-membrane-antigen-targeted-imaging-with-18f-dcfpyl-in-high-grade-gliomas
#1
Roberto Andres Salas Fragomeni, Joshua R Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B Solnes, Mehrbod S Javadi, Zsolt Szabo, Martin G Pomper, Steven P Rowe
High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients...
July 22, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28733442/-89-zr-lumretuzumab-pet-imaging-before-and-during-her3-antibody-lumretuzumab-treatment-in-patients-with-solid-tumors
#2
Frederike Bensch, Laetitia E Lamberts, Michaël M Smeenk, Annelies Jorritsma-Smit, Marjolijn N Lub-de Hooge, Anton G T Terwisscha van Scheltinga, Johan R de Jong, Jourik A Gietema, Carolina P Schröder, Marlene Thomas, Wolfgang Jacob, Keelara Abiraj, Celine Adessi, Georgina Meneses-Lorente, Ian James, Martin Weisser, Adrienne H Brouwers, Elisabeth G de Vries
Purpose: We evaluated biodistribution and tumor targeting of (89)Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody. <p>Experimental design: 20 patients with histologically confirmed HER3-expressing tumors received (89)Zr-lumretuzumab and underwent Positron Emission Tomography (PET). In Part A, (89)Zr-lumretuzumab was given with additional, escalating doses of unlabeled lumretuzumab and scans were performed 2, 4 and 7 days postinjection to determine optimal imaging conditions...
July 21, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28730266/-malignant-melanoma-current-status
#3
REVIEW
J K Winkler, K Buder-Bakhaya, A Dimitrakopoulou-Strauss, A Enk, J C Hassel
CLINICAL ISSUE: The incidence of malignant melanoma is continuously increasing. The prognosis of metastatic disease is still limited. STANDARD TREATMENT: Until a few years ago palliative chemotherapy with a limited response rate was the standard treatment for metastatic melanoma. TREATMENT INNOVATIONS: Immunotherapy and targeted therapy provide new treatment options. Immune checkpoint inhibitors have significantly improved the prognosis. DIAGNOSTIC WORK-UP: Regional lymph node sonography, computed tomography (CT) of the neck, chest and abdomen and brain magnetic resonance imaging (MRI) are routinely used...
July 20, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28709149/uptake-of-psma-ligands-in-normal-tissues-is-dependent-on-tumor-load-in-patients-with-prostate-cancer
#4
Florian C Gaertner, Khalil Halabi, Hojjat Ahmadzadehfar, Stefan Kürpig, Elisabeth Eppard, Charalambos Kotsikopoulos, Nikolaos Liakos, Ralph A Bundschuh, Holger Strunk, Markus Essler
Radioligand therapy (RLT) with Lu-177-labeled PSMA-ligands is a new therapy option for prostate cancer. Biodistribution in normal tissues is of interest for therapy planning. We evaluated if the biodistribution of Ga-68-PSMA-11 is influenced by tumor load. RESULTS: In patients with high tumor load, SUVmean was reduced to 61.5% in the lacrimal glands, to 56.6% in the parotid glands, to 63.7% in the submandibular glands, to 61.3% in the sublingual glands and to 55.4% in the kidneys (p < 0...
July 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28708601/synergistic-and-targeted-therapy-with-a-procaspase-3-activator-and-temozolomide-extends-survival-in-glioma-rodent-models-and-is-feasible-for-the-treatment-of-canine-malignant-glioma-patients
#5
Avadhut D Joshi, Rachel C Botham, Lisa J Schlein, Howard S Roth, Antonella Mangraviti, Alexandra Borodovsky, Betty Tyler, Steve Joslyn, Jayme S Looper, Michael Podell, Timothy M Fan, Paul J Hergenrother, Gregory J Riggins
PURPOSE: Glioblastoma is a deadly brain cancer with a median survival time of ~15 months. Ionizing radiation plus the DNA alkylator temozolomide (TMZ) is the current standard therapy. PAC-1, a procaspase-3 activating small molecule, is blood-brain barrier penetrant and has previously demonstrated ability to synergize with diverse pro-apoptotic chemotherapeutics. We studied if PAC-1 could enhance the activity of TMZ, and whether addition of PAC-1 to standard treatment would be feasible in spontaneous canine malignant gliomas...
July 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28682793/impact-of-pet-and-mri-threshold-based-tumor-volume-segmentation-on-patient-specific-targeted-radionuclide-therapy-dosimetry-using-clr1404
#6
Abigail E Besemer, Benjamin Titz, Joseph J Grudzinski, Jamey P Weichert, John S Kuo, H Ian Robins, Lance T Hall, Bryan P Bednarz
Variations in tumor volume segmentation methods in targeted radionuclide therapy (TRT) may lead to dosimetric uncertainties. This work investigates the impact of PET and MRI threshold-based tumor segmentation on TRT dosimetry in patients with primary and metastatic brain tumors. In this study, PET/CT images of five brain cancer patients were acquired at 6, 24, and 48 h post-injection of (124)I-CLR1404. The tumor volume was segmented using two standardized uptake value (SUV) threshold levels, two tumor-to-background ratio (TBR) threshold levels, and a T1 Gadolinium-enhanced MRI threshold...
July 6, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28680873/amino-acid-pet-and-mr-perfusion-imaging-in-brain-tumours
#7
REVIEW
Christian P Filss, Francesco Cicone, Nadim Jon Shah, Norbert Galldiks, Karl-Josef Langen
PURPOSE: Despite the excellent capacity of the conventional MRI to image brain tumours, problems remain in answering a number of critical diagnostic questions. To overcome these diagnostic shortcomings, PET using radiolabeled amino acids and perfusion-weighted imaging (PWI) are currently under clinical evaluation. The role of amino acid PET and PWI in different diagnostic challenges in brain tumours is controversial. METHODS: Based on the literature and experience of our centres in correlative imaging with PWI and PET using O-(2-[(18)F]fluoroethyl)-l-tyrosine or 3,4-dihydroxy-6-[(18)F]-fluoro-l-phenylalanine, the current role and shortcomings of amino acid PET and PWI in different diagnostic challenges in brain tumours are reviewed...
2017: Clinical and Translational Imaging: Reviews in Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28680216/extraneural-metastases-in-an-operated-case-of-pinealoblastoma-identified-on-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#8
Piyush Chandra, Sneha Shah, Archi Agrawal, Nilendu Purandare, Venkatesh Rangarajan
Extraneural (EN) metastases and leptomeningeal (LM) metastases from certain primary central nervous system (CNS) tumors, such as pinealoblastomas, are not very common and mostly detected on autopsy. Clinical detection of this entity is, however, very rare and can be attributed to increasing overall survival or probably increased use of surveillance imaging in patients with brain tumors. We demonstrate through this case the potential adjunctive role of positron emission tomography/computed tomography in the identification of asymptomatic LM/EN metastases in high-risk primary CNS tumors...
July 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28670184/unusual-asymptomatic-fluorodeoxyglucose-avid-pheochromocytoma-in-a-case-of-myxoid-liposarcoma-of-the-extremity-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#9
Divya Shivdasani, Natasha Singh, Melvika Pereira, Anand Zade
Sarcomas are a heterogeneous group of rare tumors and arise either from soft tissue or from bone. Soft-tissue sarcomas (STSs) initially metastasize to the lungs. Metastases to extrapulmonary sites such as liver, brain, and soft tissue distant from primary tumor usually develop later. However, cases with isolated adrenal metastasis without disseminated disease have been reported in literature. We present a case of primary myxoid liposarcoma of the lower limb, in which staging (18)-F fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan detected a suspicious FDG avid adrenal lesion which eventually on resection was diagnosed as asymptomatic pheochromocytoma...
July 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28660218/diagnosis-of-brain-tumors-using-amino-acid-transport-pet-imaging-with-18-f-fluciclovine-a-comparative-study-with-l-methyl-11-c-methionine-pet-imaging
#10
Naohiro Tsuyuguchi, Yuzo Terakawa, Takehiro Uda, Kosuke Nakajo, Yonehiro Kanemura
OBJECTIVES: (18)F-fluciclovine (trans-1-amino-3-[(18)F] fluorocyclobutanecarboxylic acid, [FACBC]) is an artificial amino acid radiotracer used for positron emission tomography (PET) studies, which is metabolically stable in vivo and has a long half-life. It has already been shown that FACBC-PET is useful for glioma imaging. However, there have been no reports evaluating the efficiency of FACBC-PET in the diagnosis of brain tumors in comparison with other PET tracers in clinical studies...
2017: Asia Oceania Journal of Nuclear Medicine & Biology
https://www.readbyqxmd.com/read/28654379/multimodal-imaging-of-patients-with-gliomas-confirms-11-c-met-pet-as-a-complementary-marker-to-mri-for-noninvasive-tumor-grading-and-intraindividual-follow-up-after-therapy
#11
Kai R Laukamp, Florian Lindemann, Matthias Weckesser, Volker Hesselmann, Sandra Ligges, Johannes Wölfer, Astrid Jeibmann, Bastian Zinnhardt, Thomas Viel, Michael Schäfers, Werner Paulus, Walter Stummer, Otmar Schober, Andreas H Jacobs
The value of combined L-( methyl-[(11)C]) methionine positron-emitting tomography (MET-PET) and magnetic resonance imaging (MRI) with regard to tumor extent, entity prediction, and therapy effects in clinical routine in patients with suspicion of a brain tumor was investigated. In n = 65 patients with histologically verified brain lesions n = 70 MET-PET and MRI (T1-weighted gadolinium-enhanced [T1w-Gd] and fluid-attenuated inversion recovery or T2-weighted [FLAIR/T2w]) examinations were performed. The computer software "visualization and analysis framework volume rendering engine (Voreen)" was used for analysis of extent and intersection of tumor compartments...
January 1, 2017: Molecular Imaging
https://www.readbyqxmd.com/read/28645205/aquaporin-positron-emission-tomography-differentiates-between-grade-iii-and-iv-human-astrocytoma
#12
Yuji Suzuki, Yukihiro Nakamura, Kenichi Yamada, Satoshi Kurabe, Kouichirou Okamoto, Hiroshi Aoki, Hiroki Kitaura, Akiyoshi Kakita, Yukihiko Fujii, Vincent J Huber, Hironaka Igarashi, Ingrid L Kwee, Tsutomu Nakada
BACKGROUND: Aquaporin (AQP) water channels play a significant role in mesenchymal microvascular proliferation and infiltrative growth. AQPs are highly expressed in malignant astrocytomas, and a positive correlation is observed between their expression levels and histological tumor grade. OBJECTIVE: To examine the utility of aquaporin positron emission tomography (PET) for differentiating between astrocytoma grade III and grade IV using the AQP radioligand [ 11 C]TGN-020...
June 21, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28640707/response-assessment-in-neuro-oncology-clinical-trials
#13
Patrick Y Wen, Susan M Chang, Martin J Van den Bent, Michael A Vogelbaum, David R Macdonald, Eudocia Q Lee
Development of novel therapies for CNS tumors requires reliable assessment of response and progression. This requirement has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vascular permeability, such as antiangiogenic therapies. In addition, most tumors have a nonenhancing component that can be difficult to accurately quantify. To improve the response assessment in neuro-oncology and to standardize the criteria that are used for different CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28640699/brain-tumor-imaging
#14
Kevin M Brindle, José L Izquierdo-García, David Y Lewis, Richard J Mair, Alan J Wright
Modern imaging techniques, particularly functional imaging techniques that interrogate some specific aspect of underlying tumor biology, have enormous potential in neuro-oncology for disease detection, grading, and tumor delineation to guide biopsy and resection; monitoring treatment response; and targeting radiotherapy. This brief review considers the role of magnetic resonance imaging and spectroscopy, and positron emission tomography in these areas and discusses the factors that limit translation of new techniques to the clinic, in particular, the cost and difficulties associated with validation in multicenter clinical trials...
July 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28623811/residential-exposure-to-pesticides-as-risk-factor-for-childhood-and-young-adult-brain-tumors-a-systematic-review-and-meta-analysis
#15
REVIEW
Geneviève Van Maele-Fabry, Laurence Gamet-Payrastre, Dominique Lison
BACKGROUND: Accumulating evidence suggests a positive association between exposure to non-agricultural pesticides and childhood brain tumors (CBT). OBJECTIVE: (1) To conduct a systematic review and meta-analysis of published studies on the association between residential/household/domestic exposure to pesticides and childhood brain tumors. (2) To clarify variables that could impact the results. METHODS: Publications in English were identified from a MEDLINE search through 28 February 2017 and from the reference list of identified publications...
June 14, 2017: Environment International
https://www.readbyqxmd.com/read/28619837/differentiation-between-treatment-induced-necrosis-and-recurrent-tumors-in-patients-with-metastatic-brain-tumors-comparison-among-11-c-methionine-pet-fdg-pet-mr-permeability-imaging-and-mri-adc-preliminary-results
#16
N Tomura, M Kokubun, T Saginoya, Y Mizuno, Y Kikuchi
BACKGROUND AND PURPOSE: In patients with metastatic brain tumors after gamma knife radiosurgery, the superiority of PET using (11)C-methionine for differentiating radiation necrosis and recurrent tumors has been accepted. To evaluate the feasibility of MR permea- bility imaging, it was compared with PET using (11)C-methionine, FDG-PET, and DWI for differentiating radiation necrosis from recurrent tumors. MATERIALS AND METHODS: The study analyzed 18 lesions from 15 patients with metastatic brain tumors who underwent gamma knife radiosurgery...
June 15, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28612247/-18-f-fluorothymidine-pet-imaging-in-gliomas-an-update
#17
Alexandra Nikaki, George Angelidis, Roxani Efthimiadou, Ioannis Tsougos, Varvara Valotassiou, Konstantinos Fountas, Vasileios Prasopoulos, Panagiotis Georgoulias
Brain neoplasms constitute a group of tumors with discrete differentiation grades, and therefore, course of disease and prognosis. Magnetic resonance imaging (MRI) remains the gold standard method for the investigation of central nervous system tumors. However, MRI suffers certain limitations, especially if radiation therapy or chemotherapy has been previously applied. On the other hand, given the development of newer radiopharmaceuticals, positron emission tomography (PET) aims to a better investigation of brain tumors, assisting in the clinical management of the patients...
June 13, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28612035/method-for-detecting-voxelwise-changes-in-fluorodeoxyglucose-positron-emission-tomography-brain-images-via-background-adjustment-in-cancer-clinical-trials
#18
Lei Qin, Armin Schwartzman, Keisha McCall, Nezamoddin N Kachouie, Jeffrey T Yap
An important challenge to using fluorodeoxyglucose-positron emission tomography (FDG-PET) in clinical trials of brain tumor patients is to identify malignant regions whose metabolic activity shows significant changes between pretreatment and a posttreatment scans in the presence of high normal brain background metabolism. This paper describes a semiautomated processing and analysis pipeline that is able to detect such changes objectively with a given false detection rate. Image registration and voxelwise comparison of the pre- and posttreatment images were performed...
April 2017: Journal of Medical Imaging
https://www.readbyqxmd.com/read/28605532/pet-imaging-in-patients-with-meningioma-report-of-the-rano-pet-group
#19
Norbert Galldiks, Nathalie L Albert, Michael Sommerauer, Anca L Grosu, Ute Ganswindt, Ian Law, Matthias Preusser, Emilie Le Rhun, Michael A Vogelbaum, Gelareh Zadeh, Frédéric Dhermain, Michael Weller, Karl-Josef Langen, Jörg C Tonn
Meningiomas are the most frequent non-glial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly magnetic resonance imaging (MRI) or rarely computed tomography (CT). Most common treatment options are neurosurgical resection and radiotherapy, e.g., radiosurgery or external fractionated radiotherapy. For follow-up after treatment, structural imaging techniques such as MRI or CT are used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes...
June 12, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28596159/in-vivo-relationship-between-hypoxia-and-angiogenesis-in-human-glioblastoma-a-multimodal-imaging-study
#20
Keven Ferreira da Ponte, David Hassanein Berro, Solène Collet, Jean-Marc Constans, Evelyne Emery, Samuel Valable, Jean-Sébastien Guillamo
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. This aggressiveness is in part attributed to the closely interrelated phenomena, tumor hypoxia and angiogenesis, although few in vivo data exist in human brain tumors. This work aims to study hypoxia and angiogenesis, in vivo and in situ, in patients admitted with GBM using multimodal imaging. Methods: 23 GBM patients were assessed by [(18)F]-FMISO PET and conventional and perfusion MRI prior to surgery. The level and location of hypoxia ([(18)F]-FMISO uptake, evaluated by tumor/blood ratio, T/B), vascularization (cerebral blood volume, CBV) and vascular permeability (contrast enhancement after gadolinium injection) were analyzed...
June 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
84290
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"